A randomized, double-blind, placebo-controlled study of XL784 administered orally to subjects with albuminuria due to diabetic nephropathy.

Trial Profile

A randomized, double-blind, placebo-controlled study of XL784 administered orally to subjects with albuminuria due to diabetic nephropathy.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs XL 784 (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2010 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Symphony Evolution added as trial sponser as reported by ClinicalTrials.gov.
    • 16 Oct 2007 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top